Vioxx
Celebrex
Bextra
COX-2 Inhibitors
Crestor
Neurontin
Zyprexa
Ephedra
Strattera
Remicade
Accutane
Serzone
Serevent
Tamoxifen
Baycol
Fen Phen
Rezulin
Meridia
PPA
Propulsid
Avara
Permax
Anti-Depressants
OxyContin
Tysabri
Pemoline
 
Guidant Defibrillators
Guidant Ancure Device
Sulzer Hip Replacement
Contraceptive Devices
Breast Implants
 
Welding Rods
Asbestos
Mesothelioma
Lead Poisoning
Silica
 
Cerebral Palsy
Erb's Palsy
Birth Injury
Surgical Mistake
Cancer Misdiagnosis
Nursing Home Negligence
Hospital Negligence
 
Car Accidents
Plane Accidents
Boat Accidents
Bus Accidents
Motorcycle Acc
Brain Injury
Spinal Cord Injury
Dodge Truck and SUV Recall
 
Insurance Bad Faith
Slip and Fall
Dog Bite Injury
Inadequate Security
Recall Forum
Consumer Pro
Sexual Abuse
Product Liability
General Inquiries

Resources

Network

Peers

Remicade Information

In August of 1998, Remicade was approved for the treatment of Crohn’s disease. In November of 1999, the FDA approved Remicade to treat rheumatoid arthritis. Over 150,000 people worldwide have taken Remicade, made by Johnson & Johnson's Centocor unit. Remicade controls the pain associated with rheumatoid arthritis, the chronic inflammation in the lining of the joints and the pain from Crohn's disease, an intestinal disease. Known generically as Infliximab, Remicade is an immune-suppressing drug.  

    The concerns for Remicade side effects, including Tuberculosis arose from a study conducted by researchers from the FDA, published in the New England Journal of Medicine. Their study, published in the Oct. 11, 2001 issue, found that from August 1998 to May 2000, 70 people treated with Remicade developed Tuberculosis (TB), and four of those patients died as a result. The report explains that TB cases occur in arthritis sufferers at an annual rate of approximately 6.2 cases per 100,000. However, for patients taking Remicade the rate was 24.4 per 100,000, the researchers said.

 



    The results of the Remicade study suggest that taking the drug nearly quadruples the risk of developing tuberculosis. Since the study, the FDA has issued a series of warnings and now requires the drug to carry a special "black box warning" on its label, warning of the risk of tuberculosis. The revised labeling indicates that patients should be tested and treated for latent (inactive), TB prior to infliximab therapy, so that the immune-suppressing medication will not increase the tuberculosis risk.

    Symptoms of Tuberculosis include severe cough, chest pain, night sweats, chills, weight loss, fever, fatigue and weight loss.




Please share your opinion with us.
Your name:
Your email:
How dangerious do you think this is?:
Write a review for this product:

Copyright 2006 LawsuitResources.com
Ology Midlands Regional Principal - Qantas Airline - What Is Probate - Easy Recipes - Street Paintings